On Friday 10 June, the ACP of the National Health Care Institute met to discuss the reimbursement of risdiplam. The Zorginstituut’s advice was published on 19 July. They see the importance of the third drug for SMA. The Committee recommends that the medicine be reimbursed from the health insurer’s basic package for patients up to the age of 25, provided that the price falls sharply. In addition, they call on all parties to work together and make risdiplam available under conditional authorization for patients older than 25 years. Finally, the Minister of Health, Welfare and Sport (VWS) is asked to start price negotiations with the manufacturer and only approve the above if the price is significantly reduced.
Lees here the complete advice of the ACP.